Paris and London (ots/PRNewswire) - New Agreement Provides Healthcare Professionals with Streamlined, Cost-Effective Options for Accessing the CyberKnife® and TomoTherapy® Systems
Accuray Europe and GE Capital Healthcare Equipment Finance announced today they have signed a collaboration agreement to develop sustainable financing options that will increase market access to the CyberKnife® and TomoTherapy® Systems. These innovative solutions provide excellent treatment outcomes for a wide range of cancerous and non-cancerous tumors. The new financing program will make it even easier for clinicians throughout Europe to offer their patients a non-invasive treatment option that delivers precise radiation therapy while maximizing patients' quality of life during and after treatment.
(Logo: http://photos.prnewswire.com/prnh/20151126/291246LOGO )
"In today's complex global healthcare environment, it's important to keep the needs of physicians and their patients top-of-mind. The new financing program with GE Capital Healthcare Equipment Finance underscores our commitment to providing the cancer community with world-class options for accessing and treating cancer," said Lionel Hadjadjeba, senior vice president, worldwide commercial operations of Accuray.
- The Accuray and GE Capital Healthcare Equipment Finance
collaboration enables hospitals, clinics and medical practitioners
to lease Accuray equipment and services through a turnkey offering
that combines bunker construction, hardware, software, services and
ongoing maintenance costs into one finance agreement. The aim is to
provide a flexible and sustainable funding solution for healthcare
investments that make it possible for clinicians and patients to
access Accuray's precise, novel tumor treatments.
- Multiple customers have already experienced how flexible and
seamless financing radiotherapy systems throughout the entire
procurement process can be. Accuray and GE Capital Healthcare
Equipment Finance have most recently signed and closed two
transactions in France with installations taking place over the
early part of 2016. For example, Hospices Civils de Lyon (HCL),
Lyon in France received financing for the acquisition of their
TomoTherapy Systems through this collaboration.
"Our financing solutions aim at making life-saving technology more accessible to healthcare institutions, helping them provide superior clinical care and allowing them to focus their resources where it matters most to patients," added Christian Bernhard, General Manager, GE Capital Healthcare Equipment Finance in Europe.
About the CyberKnife and TomoTherapy Systems
The Accuray CyberKnife® M6(TM) Series and TomoTherapy® H(TM) Series treatment solutions cover the entire spectrum of radiation therapy needs. The CyberKnife M6 Series enables precise, high-quality, dose distributions to be confidently delivered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The CyberKnife System is the only robotic full-body radiosurgery system available today. The TomoTherapy H Series efficiently enables physicians to customize treatment plans for the entire range of radiation therapy patients and disease types. Its innovative design enables treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity-modulated radiation for optimal sparing of healthy tissue and critical structures.
Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit http://www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to market adoption and access, clinical applications, clinical results, patient outcomes and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 28, 2015, the company's reports on Form 10-Q, filed on November 5, 2015 and February 1, 2016, and the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
About GE Capital International
GE Capital International focuses on sectors where it can share GE's 130+ year industrial heritage with customers - energy, healthcare, transportation, power & water, aviation, oil & gas. Through its 'Access GE' programme, GE Capital gives customers access to GE's experience and expertise to help solve their business issues and challenges. For more information, visit http://www.gecapital.eu.
Sancie Nakarat for Accuray
Original-Content von: Accuray, übermittelt durch news aktuell
E-mail: email@example.com. Katja Antila for GE Capital